Design Therapeutics, Inc. (DSGN) Dividend History

Design Therapeutics, Inc. is a biotechnology company focused on developing genetic medicines for serious neurological and rare diseases. They utilize a proprietary genetic medicine platform to create targeted therapies aimed at addressing the underlying causes of these conditions.

6005 Hidden Valley Road, Carlsbad, CA, 92011
Phone: 858-293-4900
Website: https://www.designtx.com

Dividend History

Design Therapeutics, Inc. currently does not pay dividends

Company News

Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

CARLSBAD, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2024 RBC Capital Markets Healthcare Conference on Wednesday, May 15, 2024, at 11:30 a.m. ET in New York.

GlobeNewswire Inc.
Design Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying

The Dow Jones index closed lower by over 150 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. FTC Solar The Trade: FTC Solar, Inc. (NASDAQ: FTCI) Director Ahmad R Chatila acquired a total of 92,600 shares an average price of $0.55. To acquire these shares, it cost around $50,930. What’s Happening: On March 13, FTC ...

Benzinga

Featured Companies: FTCI
Design Therapeutics, Inc. (DSGN) Upgraded to Buy: Here's What You Should Know

Design Therapeutics, Inc. (DSGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research
Why Shares of Design Therapeutics Are Plummeting on Tuesday

The biotech company released phase 1 trial details regarding a Friedreich ataxia therapy.

The Motley Fool
Nvidia climbs, D.R. Horton gets a Buffett boost, and other stocks on the move

Nvidia was the subject of two bullish analyst notes on Tuesday.

MarketWatch

Featured Companies: AMC BK BRK.A BRK.B CFG CMA COF DHI GLTO GM KEY LEN NVDA RUM TLSA

Page data last updated 07/23/2025 12:37:57 UTC